Use of injectable platelet‐rich fibrin in the treatment of plasma cell mucositis of the oral cavity refractory to corticosteroid therapy: A case report
Roberta Gasparro,Daniela Adamo,Michele Masucci,Gilberto Sammartino,Michele Davide Mignogna
DOI: https://doi.org/10.1111/dth.13062
2019-08-23
Dermatologic Therapy
Abstract:Plasma Cell Mucositis (PCM) is a rare benign disease affecting adults characterized by an erythematous mucosa, an epithelial hyperplasia and a dense submucosal infiltration of mainly mature plasma cells. PCM has been treated with topical, intralesional and systemic corticosteroids, antibiotics and topical cyclosporin with unreliable results and questionable benefits.Here, we present a case of PCM, refractory to previous treatments, treated with i‐PRF (injectable platelet‐rich fibrin) injections. The infiltrations were performed once a week for two months. There were no adverse reactions to the treatment. The pain gradually reduced until 0 at the fourth infiltration and the patient remained free of pain during the whole study period. Clinically, we didn't obtain a complete healing of the lesion but a reduced perilesional inflammatory infiltrate was observed at a distance. Therefore, we can conclude that i‐PRF has been effective in the management of pain in PMC, but does not result in complete healing of the disease.This article is protected by copyright. All rights reserved.
dermatology
What problem does this paper attempt to address?